ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-OR91

Performance of eGFR Equations for Drug Dosing in Kidney Transplant Recipients

Session Information

Category: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

  • 2000 Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)


  • Hundemer, Gregory L., Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • Sood, Manish M., Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • Akbari, Ayub, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

For kidney transplant recipients (KTRs), drug dosing is most commonly determined by using eGFR as a surrogate for graft function. Which eGFR equation performs best for drug dosing in KTRs remains unknown.


Cross-sectional study of 415 stable KTRs from Canada and New Zealand with same-day values of serum creatinine and cystatin C along with measured GFR (99mTc-DTPA). We assessed the performance for drug dosing of CKD-EPI (both indexed to a standardized body surface area [BSA] of 1.73m2 [mL/min/1.73m2] and non-indexed to account for actual BSA [mL/min]) and Cockcroft-Gault (via 3 different weights: ideal, adjusted ideal, and actual body weight) eGFR equations relative to measured GFR based upon recommended renal dosing of 8 medications commonly prescribed to KTRs: famciclovir, ganciclovir, trimethoprim/sulfamethoxazole, oseltamivir, ciprofloxacin, levofloxacin, lamivudine, and nimatrelvir/ritonavir. The primary outcome was proportion of drug dosing discordance (under- or over-dosing) overall and stratified by obesity status (BMI < or ≥30kg/m2).


The non-indexed CKD-EPI equations led to a lower proportion of drug dosing discordance compared to the indexed CKD-EPI equations across all study drugs (Figure). The Cockcroft-Gault equations based upon adjusted ideal and actual body weight led to a lower proportion of drug dosing discordance compared to ideal body weight. These findings were most pronounced among obese KTRs. Overall, the non-indexed 2021 CKD-EPI eGFR equations showed the lowest proportion of drug dosing discordance across all study drugs.


When employing eGFR-based drug dosing for KTRs, actual BSA should be accounted for to mitigate the risks of under- or over-dosing. The non-indexed 2021 CKD-EPI equations provide the most accurate eGFR-based guidance for appropriate drug dosing among KTRs.